Yiqiu Xia

Yiqiu Xia

Auto-generated profile, based on publicly available information

Yiqiu Xia

Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, 15213, United States

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
SHSi-Jie Hao
Si-Jie Hao
YWYuan Wan
Yuan Wan
YXYi-Qiu Xia
Yi-Qiu Xia
XZXin Zou
Xin Zou
SZSi-Yang Zheng
Si-Yang Zheng

21 July 2021 in Bioactive Materials
Verified
Journal Article
Open access
YCYundi Chen
Yundi Chen
WXWang Li Xue
Wang Li Xue
MZMingfeng Zheng
Mingfeng Zheng
CZChuandong Zhu
Chuandong Zhu
GWGuosheng Wang
Guosheng Wang
YWYuan Wan
Yuan Wan
Immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 have been approved for the treatment of a variety of cancers. However, the efficacy of antibody-based ICIs could be further improved by mitigating anti-drug antibodies, proteolytic cleavage, and on-target off-tumor toxicity. One strategy for accomplishing this is through the use of extracellular vesicles (EVs), cell derived submicron vesicles with many unique properties. We constructed an engineered MDA-MB-231 cell line for harvesting EVs. This was accomplished by overexpressing a high-affinity variant human PD-1 protein (havPD-1), while simultaneously knocking out intrinsic PD-L1 and beta-2 microglobulin. The engineered havPD-1 EVs reduced PD-L1 overexpressing cancer cell proliferation and induced cellular apoptosis. Moreover, the EVs were shown to efficiently block PD-L1 mediated T cell suppression. Meanwhile antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity were not observed. The havPD-1 EVs treatment resulted in robust anti-tumor activity in both preventative co-implantation and therapeutic xenograft tumor models reconstituted with human T cells. The efficacy of the havPD-1 EVs was shown to be comparable to clinical anti-PD1 monoclonal antibodies. Additionally, loading the havPD-1 EVs with a potent PARP inhibitor was shown to further augment treatment efficacy. In brief, the engineered universal EVs harboring havPD-1 proteins can be used for cancer concurrent immunotherapy and chemotherapy.

5 December 2016 in Small
Verified
Journal Article
Closed access
PDF file
YXYiqiu Xia
Yiqiu Xia
YTYi Tang
Yi Tang
Xu YuXu Yu
Xu Yu
YWYuan Wan
Yuan Wan
YCYizhu Chen
Yizhu Chen
SZSi-Yang Zheng
Si-Yang Zheng

1 March 2021 in Bioactive Materials
Verified
Journal Article
Open access
ZQZachary Quinn
Zachary Quinn
WMWenjun Mao
Wenjun Mao
YXYiqiu Xia
Yiqiu Xia
RJRhea John
Rhea John
YWYuan Wan
Yuan Wan
Triple negative breast cancer (TNBC) is a heterogeneous subset of breast cancer characterized by its lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), which altogether prevents TNBC from being treated effectively. For many years, the treatment paradigms and overall survival of patients with TNBC have remained largely stagnant. Recent attempts to convert cold tumors to hot tumors by promoting antigen presentation have shown increased T cell infiltration and significantly induced immune responses for tumor killing. Inspired by this concept, the expression of specific targetable antigens on TNBC cells may further benefit relevant targeted drug delivery. In this study, we successfully conferred sufficient HER2 on the surface of TNBC MDA-MB-231 cells via simple EV-plasma membrane fusion with HER2+ extracellular vesicles (EV) derived from HER2 overexpressing BT-474 cells. Subsequently, anti-HER2 antibody conjugated paclitaxel-loaded liposomes were used for HER2-targeted drug delivery. Our findings demonstrated this HER2 grafting, in conjunction with targeted drug delivery, can improve the treatment efficacy in vitro and in vivo. This novel approach represents a facile method of altering cell membrane antigen presentation via convenient EVs uptake and may pave the way for the burgeoning wave of targeted therapy and/or immunotherapy.

4 October 2018 in Small
Verified
Journal Article
Closed access
PDF file
YXYiqiu Xia
Yiqiu Xia
YWYuan Wan
Yuan Wan
SHSijie Hao
Sijie Hao
MNMerisa Nisic
Merisa Nisic
RHRamdane Harouaka
Ramdane Harouaka
SZSi-Yang Zheng
Si-Yang Zheng